deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04820933

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors With Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons With Chronic Treated HIV.

Sponsor: Merck Sharp & Dohme LLC

Conditions Cardiovascular Risk Factor HIV I Infection Lipid Metabolism Disorders
Interventions Doravirine 100 Mg
Updated 15 times since 2021 Last updated: Jan 28, 2026 Started: Mar 1, 2024 Primary completion: Oct 1, 2025 Completion: Dec 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04820933, this EARLY_PHASE1 trial focuses on Cardiovascular Risk Factor and HIV I Infection and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 15 times since 2024, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Jun 2022 · 8 months · monthly snapshot~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshot~Dec 2022 – ~Jun 2023 · 6 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Nov 2023 · 4 months · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Apr 2024 · 3 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Nov 2025 · 5 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Jun 2025 — Nov 2025 [monthly]

    Recruiting EARLY_PHASE1

  4. Apr 2025 — Jun 2025 [monthly]

    Recruiting EARLY_PHASE1

  5. Sep 2024 — Apr 2025 [monthly]

    Recruiting EARLY_PHASE1

▶ Show 10 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting EARLY_PHASE1

  2. Apr 2024 — Jul 2024 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  3. Jan 2024 — Apr 2024 [monthly]

    Not Yet Recruiting EARLY_PHASE1

  4. Nov 2023 — Jan 2024 [monthly]

    Not Yet Recruiting EARLY_PHASE1

  5. Jul 2023 — Nov 2023 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    Status: Suspended → Not Yet Recruiting

  6. Jun 2023 — Jul 2023 [monthly]

    Suspended EARLY_PHASE1

    Status: Recruiting → Suspended

  7. Dec 2022 — Jun 2023 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  8. Jun 2022 — Dec 2022 [monthly]

    Not Yet Recruiting EARLY_PHASE1

  9. Oct 2021 — Jun 2022 [monthly]

    Not Yet Recruiting EARLY_PHASE1

  10. Apr 2021 — Oct 2021 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • University of Texas Southwestern Medical Center
Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations